At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 97 enrolled
Drug / intervention
rosuvastatindrug
Likely dose
rosuvastatin 10mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-labelled, Single Arm, Phase IV Clinical Study to Evaluate the Impact of Rosuvastatin on Lipid Levels in Patients With Metabolic Syndrome (EFFORT)
In Brief
A Phase 4 clinical trial evaluating rosuvastatin for Metabolic Syndrome. Completed, enrolled 97 participants across 6 sites.
Detailed Summary
The primary objective is to evaluate the efficacy of rosuvastatin therapy on plasma lipid profile (Low Density Lipoprotein (LDL), High-Density Lipoprotein (HDL), total cholesterol, triglyceride) in patients with metabolic syndrome.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetabolic Syndrome
CountriesTurkey (Türkiye)
Collaborators--
Timeline
Phase 4CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartDec 2008
First PostedDec 2008
Primary CompletionMar 2010
TodayJul 2026
First PostedDec 30, 2008
Enrollment StartDec 1, 2008
Primary CompletionMar 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 17.5 years ago
Interventions
rosuvastatindrug
medication start dose is 10mg. After 6 weeks of treatment will be force-titrated to 20mg.